Keywords
Ovarian cancer
Biomarkers
lncRNA
miRNA
Early diagnosis
Submitted : 2025-05-06
Accepted : 2025-05-21
Published : 2025-06-05
Abstract
Ovarian cancer ranks as the deadliest malignancy among female reproductive system cancers, posing a significant threat to women’s health. Around seven out of ten patients are diagnosed only after reaching progressive disease phases, a phenomenon closely linked to three key factors: the disease’s hidden onset location, lack of early symptoms, and absence of reliable early diagnostic methods. Therefore, identifying early diagnostic biomarkers and therapeutic targets is critical. Exosomes participate in various phases of ovarian tumorigenesis, including transforming normal cells into cancerous cells, immune regulation, invasion, metastasis, drug resistance, and angiogenesis, making them promising biomarkers for early ovarian cancer detection. This review summarizes current research on exosomal long non-coding RNAs (lncRNAs), miRNAs, and related proteins in ovarian cancer diagnosis. Exosome-based biomarkers have shown potential advantages, including high sensitivity, specificity, stability, and non-invasive accessibility. The study concludes that while exosomes hold significant diagnostic potential for ovarian cancer, additional investigations are required to standardize detection methods, validate clinical applicability, and elucidate underlying molecular mechanisms.
References
Jiao XF, Gao QL, 2024, Progress in Ovarian Cancer Biomarkers. Journal of Practical Oncology, 39(5): 401–406.
Armstrong DK, Alvarez RD, Backes FJ, et al., 2022, NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw, 20(9): 972–980.
Siegel RL, Miller KD, Jemal A, 2020, Cancer Statistics. CA Cancer J. Clin, 70(1): 7–30.
Hulstaert E, Morlion A, Levanon K, et al., 2021, Candidate RNA Biomarkers in Biofluids for Early Diagnosis of Ovarian Cancer: A Systematic Review. Gynecologic Oncology, 160(2): 633–642.
Zhou MQ, Qu HM, 2025, miRNA as Biomarkers for Ovarian Cancer Early Diagnosis: Research Progress. Hebei Medical Journal, 47(2): 313–317.
Zhang R, Siu M, Ngan H, et al., 2022, Molecular Biomarkers for the Early Detection of Ovarian Cancer. International Journal of Molecular Sciences, 23(19): 12041.
Siegel RL, Miller KD, Fuchs HE, et al., 2022, Cancer Statistics. CA: A Cancer Journal for Clinicians, 72(1): 7–33.
Cabasag CJ, Fagan PJ, Ferlay J, et al., 2022, Ovarian Cancer Today and Tomorrow: A global Assessment by World Region and Human Development Index using GLOBOCAN 2020. International Journal of Cancer, 151(9): 1535–1541.
Lyratzopoulos G, Abel GA, Brown CH, et al., 2013, Socio-demographic Inequalities in Stage of Cancer Diagnosis: Evidence from Patients with Female Breast, Lung, Colon, Rectal, Prostate, Renal, Bladder, Melanoma, Ovarian, and Endometrial Cancer. Annals of Oncology, 24(3): 843–850.
Liu FX, Wang Z, Li J, et al., 2023, Application Value of Ultrasound O-RADS Classification Combined with Contrast-enhanced Ultrasound and Serum CA125 and HE4 Detection in Diagnosing Postmenopausal Ovarian Masses. Journal of Practical Oncology, 38(4): 392–397.
Zhang YZ, Ma WW, Han MX, et al., 2024, Research Progress on Exosomes in the Diagnosis of Ovarian Cancer. Chinese Journal of Modern Medicine, 34(23): 62–67.
Bhavsar D, Raguraman R, Kim D, et al., 2024, Exosomes in Diagnostic and Therapeutic Applications of Ovarian Cancer. Journal of Ovarian Research, 17(1): 113.
Hao L, Wu W, Xu Y, et al., 2023, LncRNA-MALAT1: A Key Participant in the Occurrence and Development of Cancer. Molecules, 28(5): 2126.
Lou HY, Fan XY, Ji YY, et al., 2025, Research Progress on the Role of lncRNA linc-UBC1 in the Development and Progression of Malignant Tumors. Guangzhou Medical Journal, 2025: 1–8.
Zhang X, Xie H, Luo M, et al., 2020, A Systematic Review and Meta-analysis of Long Noncoding RNA Linc-UBC1 Expression and Prognosis and Clinicopathological Phenotypes in Human Cancers. Artificial Cells, Nanomedicine, and Biotechnology, 48(1): 875–884.
Zhao EY, Chen YL, Yi LS, et al., 2024, Association Analysis of LINC02038 with the Occurrence and Development of Endometrial Cancer. Guangzhou Medical Journal, 55(1): 18–24.
Carlevaro-Fita J, Lanzos A, Feuerbach L, et al., 2020, Cancer LncRNA Census Reveals Evidence for deep Functional Conservation of Long Noncoding RNAs in Tumorigenesis. Communications biology, 3(1): 56.
Yang M, Zhai Z, Zhang Y, et al., 2019, Clinical Significance and Oncogene Function of Long Noncoding RNA HAGLROS Overexpression in Ovarian Cancer. Archives of Gynecology and Obstetrics, 300: 703–710.
Gong J, Xu X, Zhang X, et al., 2019, LncRNA MIR4435-2HG is a Potential Early Diagnostic Marker for Ovarian Carcinoma. Acta Biochimica et Biophysica Sinica, 51(9): 953–959.
Zhang YF, Guo JF, Cai E, et al., 2020, HOTAIR Regulates Ovarian Cancer Stem Cells and Its Mechanism. Huazhong University of Science and Technology, 395(2): 112218.
Murphy SK, Huang ZQ, Wen YQ, et al., 2006, Frequent IGF2/H19 Domain Epigenetic Alterations and Elevated IGF2 Expression in Epithelial Ovarian Cancer. Molecular Cancer Research, 4(4): 283–292.
Hu XW, Feng Y, Zhang DM, et al., 2014, A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer. Cancer Cell, 26(3): 344–357.
Fu YY, Biglia N, Wang ZW, et al., 2016, Long Non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in Epithelial Ovarian Cancer. Gynecol Oncol, 143(3): 642–649.
Gebert LFR, MacRae IJ, 2019, Regulation of microRNA Function in Animals. Nature Reviews Molecular Cell Biology, 20(1): 21–37.
Han J, LaVigne CA, Jones BT, et al., 2020, A Ubiquitin Ligase Mediates Target-directed microRNA Decay Independently of Tailing and Trimming. Science, 370(6523): eabc9546.
Iorio MV, Visone R, Di Leva G, et al., 2007, MicroRNA Signatures in Human Ovarian Cancer. Cancer Research, 67(18): 8699–8707.
Wang L, Zhu MJ, Ren AM, et al., 2014, A Ten-microRNA Signature Identified from a Genome-wide MicroRNA Expression Profiling in Human Epithelial Ovarian Cancer. PLoS One, 9(5): e96472.
Resnick KE, Alder H, Hagan JP, et al., 2009, The Detection of Differentially Expressed MicroRNAs from the Serum of Ovarian Cancer Patients Using a Novel Real-time PCR Platform. Gynecologic Oncology, 112(1): 55–59.
Zhou J, Gong GH, Tan H, et al., 2015, Urinary MicroRNA-30a-5p is a Potential Biomarker for Ovarian Serous Adenocarcinoma. Oncology Reports, 33(6): 2915–2923.
He LQ, Zhu W, Chen Q, et al., 2019, Ovarian Cancer Cell-secreted Exosomal miR-205 Promotes Metastasis by Inducing Angiogenesis. Theranostics, 9(26): 8206–8220.
Li JH, Sherman-Baust CA, Tsai-Turton M, et al., 2009, Claudin-containing Exosomes in the Peripheral Circulation of Women with Ovarian Cancer. BMC Cancer, 9: 244.
Esfandyari S, Elkafas H, Chugh RM, et al., 2021, Exosomes as Biomarkers for Female Reproductive Diseases Diagnosis and Therapy. International Journal of Molecular Sciences, 22(4): 2165.
Chanteloup G, Cordonnier M, Isambert N, et al., 2020, Membrane-bound Exosomal HSP70 as a Biomarker for Detection and Monitoring of Malignant Solid Tumours: A Pilot Study. Pilot and Feasibility Studies, 6: 35.
Wyciszkiewicz A, Kalinowska-Łyszczarz A, Nowakowski B, et al., 2019, Expression of Small Heat Shock Proteins in Exosomes from Patients with Gynecologic Cancers. Scientific Reports, 9(1): 9817.
Resnick KE, Alder H, Hagan JP, et al., 2009, The Detection of Differentially Expressed MicroRNAs from the Serum of Ovarian Cancer Patients Using a Novel Real-time PCR Platform. Gynecologic Oncology, 112(1): 55–59.
Elias KM, Fendler W, Stawiski K, et al., 2017, Diagnostic Potential for a Serum miRNA Neural Network for Detection of Ovarian Cancer. eLife, 6: e28932.
Ma HB, Li HF, 2018, Research Progress on the Application of MicroRNA in Early Diagnosis and Prognosis of Ovarian Cancer. Chinese Journal of General Practice, 16(5): 826–829.
Mitchell PS, Parkin RK, Kroh EM, et al., 2008, Circulating microRNAs as Stable Blood-based Markers for Cancer Detection. Proceedings of the National Academy of Sciences of the United States of America, 105(30): 10513–10518.
Pendlebury A, Hannan NJ, Binder N, et al., 2017, The Circulating MicroRNA-200 Family in Whole Blood are Potential Biomarker for High-grade Serous Epithelial Ovarian Cancer. Biomedical Reports, 6(3): 319–322.